RECKGIST score may predict recurrence in neurofibromatosis type 1 GISTs, potentially guiding treatment decisions, according ...
Clinical Trials Arena on MSN16d
Healx doses first subject in Phase II neurofibromatosis type 1 therapy trialHealx has dosed the first subject in the open-label Phase II INSPIRE-NF1 trial to assess the efficacy and safety of HLX-1502 in individuals with neurofibromatosis type 1 (NF1), a rare genetic disorder ...
Moertel CL, Hirbe AC, Shuhaiber HH, et al. ReNeu: A pivotal phase 2b trial of mirdametinib in children and adults with neurofibromatosis type 1 (NF1)-associated symptomatic inoperable plexiform ...
Researchers from the Wellcome Sanger Institute and partners found that genetic changes linked to neurofibromatosis type 1 (NF ...
Genetic changes alone don’t fully explain tumor growth in NF-1, pointing to other contributing factors. This insight may ...
Medical Xpress on MSN16d
Researchers challenge previous understanding of tumor growth in NF-1Despite what was previously thought, new research has shown that genetic changes alone cannot explain why and where tumors grow in those with genetic condition neurofibromatosis type 1 (NF-1).
Researchers have found in a nonrandomised pilot trial that selumetinib showed a reduction in cutaneous neurofibromatosis ...
Discover a study that used the Skindex-29 assessment to evaluate emotional wellbeing during selumetinib cycles.
Sumrall, MD The FDA has approved an oral, small molecule MEK inhibitor for adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic plexiform ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback